FBB Meet Up @ BIO 2015?

bio_convention_banner2015 

FRENCH BIOBEACH @ BIO 2015: "See you next week in Philadelphia!",  Stephane & Chrystel

We will be on the France Pavilion (Booth 2507), in meetings & walking the floor so don't hesitate to text/call us, we will be pleased to meet up with you.

Stephane B. Richard, Ph.D.  | President & Founder                          (858) 342-6807
Chrystel Gelin                        | Business Development & Marketing  | (858) 717-2592

 

PHILADELPHIA BIO 2015: FRENCH COMPANIES BECOMING A FORCE IN THE US MARKET

According to Business France nearly 75 companies and 35 partners (non- profit organizations ,research institutes, universities and clusters ..) will be on the French pavilion. This important mobilization demonstrates how the issue of this industry remains important in France. The sector is posting impressive results in recent years particularly the debut of Celletcis and DBV Technologies in the NASDAQ stock exchange.

 

Additionally, the massive growth of the following companies have attracted substantial amount of foreign investors, such as the case of Adocia, 32M € (January 2015) of Erytech Pharma € 30M (November 2014), GENFIT: € 50M (June 2014) and € 21 million (December 2014) and Hybrigenics: € 4.6M (November 2014). These figures confirm that French companies are positioning themselves competitively in the global market. In 2014, 706 million € was raised by French companies in this sector, representing a growth of + 28% compared to 2013.

The competitive clusters and some regional clusters will once again be the core of this event by bringing their companies, all under the umbrella of the French Pavilion and Business France (of which WSGR – Wilson Sonsino Goodrich & Rosati (French BioBeach long time sponsor in San Diego)– and SERVIER Laboratories are the sponsors of the French pavilion). Created in 2005, the clusters are responsible for collecting and supporting the main players in their region to enable their businesses expand globally and foster research partnerships and technology development.

Seven clusters, all present on BIO 2015 revolve around specific areas and have established relationships with many foreign scientific partners in recent years:
BIOVALLEY Alsace – Strasbourg
French ATLANTIC biotherapy - Nantes & Angers 
Biohealth CANCER - Toulouse & Limoges
EUROBIOMED - Nice & Marseille & Montpellier in South of France: www.eurobiomed.org             
LYONBIOPÔLE - Lyon and Grenoble in Rhône-Alpes
MEDICEN REGION PARIS - Paris
HEALTHCARE NUTRITION Lightfastness CLUSTER - Lille

BIO 2015 will mark the 1st year anniversary of the  Eurobiomed-Biocom partnering agreement at BIO 2014 in San Diego, from which the South Bio Alliance was born.

France also has regional clusters such as Biopôle Limagne Clermont in the Auvergne region, or Capbiotek in Brittany, specializes in marine biotechnology and focuses a large number of biotech companies. Regarding the current 446 biotechnology companies in France, there’s a total turnover of 278 million euros in 2013, an increase from the 251 million euros from the year prior. In 2013, 55 new companies  (+12% from 2012) were created.

For 2 years, France has placed innovation at the heart of its economic and industrial policy in the framework of the plan "Better to heal." Implementation of the new government in 2013, it aims to support the creation of innovative companies and research through an enabling environment and policy support strong:
- Strong University research  policies and the principle of future investments
- A structured ecosystem (competitiveness cluster, IHU (University Institute Hospitalo-) SATT (Technology Transfer Acceleration Companies), PRES (Pole of research and teaching)
- A high-level research: Institut Pasteur Genopole, CNRS, CEA, Inserm …
- Favorable tax environment: status JEI (young innovative entrepreneurs), Research Tax Credit

All these measures have enabled France to file 13,000 patents in 2014 and to strengthen its positions in Europe. As for the US market, the 2015 France Pavilion will once again be an opportunity for the French biotech actors to continue the offensive.

Source: Business France & French BioBeach